Acapatamab, a PSMA x CD3 bispecific T-cell armature, was shown to have a significant impact on the immune response to CRPC in a 133-patient phase I clinical trial, showing some anti-tumor activity and suggesting it as a potential therapeutic option for patients with CRPC. This evidence concerns the gene FOLH1 and neoplasm.